Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 Quick Ratio is 1.14 as of Mar. 2026, which is 31% above its 10-year median of 0.87. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Rubicon Research ranks worse than 60.52% on this metric.
Rubicon Research has a quick ratio of 1.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Rubicon Research's Quick Ratio or its related term are showing as below:
NSE:RUBICON'
s Quick Ratio Range Over the Past 10 Years
Min: 0.69 Med: 0.87 Max: 1.14
Current: 1.14
During the past 4 years, Rubicon Research's highest Quick Ratio was 1.14. The lowest was 0.69. And the median was 0.87.
NSE:RUBICON's Quick Ratio is ranked worse than 60.52% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.455
vs NSE:RUBICON: 1.14
Rubicon Research (NSE:RUBICON) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Rubicon Research Quick Ratio Related Terms
Rubicon Research Quick Ratio Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Quick Ratio Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Rubicon Research's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a Quick Ratio of 1.14 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Rubicon Research and its competitors. This is 31% above median its historical median of 0.87. Over the past decade, Rubicon Research's Quick Ratio has ranged from 0.69 to 1.14. According to the industry distribution chart, Rubicon Research ranks #604 out of 998 companies in the Drug Manufacturers industry, placing it in the top 60.5%.
Is Rubicon Research's Quick Ratio too high?
Rubicon Research's current Quick Ratio of 1.14 is 31% above median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 1.14. The Drug Manufacturers industry median Quick Ratio is 1.46. Rubicon Research's value of 1.14 is 21.6% below this industry median. Based on the distribution chart, Rubicon Research ranks #604 out of 998 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Quick Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #604 out of 998 companies for Quick Ratio. This places Rubicon Research in the lower half of its industry. The industry median Quick Ratio is 1.46. Rubicon Research's value of 1.14 is 21.6% below this benchmark. Historically, Rubicon Research's own Quick Ratio has ranged from 0.69 to 1.14 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 1.46, Rubicon Research has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.46, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current Quick Ratio of 1.14 is 21.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Quick Ratio is 1.14, which is 31% above median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Quick Ratio of 1.14. The current Quick Ratio is 1.14, which is 31% above median its 10-year median of 0.87 and 21.6% below the Drug Manufacturers industry median of 1.46. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Quick Ratio is 1.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
